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Diagnostics, Sun Yat-Sen University Cancer Centre, Guangzhou, China, 6 Laboratoire de Biologie du Développement et de la Différenciation, Faculté des Sciences,
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Abstract
Previous studies have reported that the tumour cells of nasopharyngeal carcinoma (NPC) exhibit recurrent chromosome
abnormalities. These genetic changes are broadly assumed to lead to changes in gene expression which are important for
the pathogenesis of this tumour. However, this assumption has yet to be formally tested at a global level. Therefore a
genome wide analysis of chromosome copy number and gene expression was performed in tumour cells micro-dissected
from the same NPC biopsies. Cellular tumour suppressor and tumour-promoting genes (TSG, TPG) and Epstein-Barr Virus
(EBV)-encoded oncogenes were examined. The EBV-encoded genome maintenance protein EBNA1, along with the putative
oncogenes LMP1, LMP2 and BARF1 were expressed in the majority of NPCs that were analysed. Significant downregulation
of expression in an average of 76 cellular TSGs per tumour was found, whilst a per-tumour average of 88 significantly
upregulated, TPGs occurred. The expression of around 60% of putative TPGs and TSGs was both up-and down-regulated in
different types of cancer, suggesting that the simplistic classification of genes as TSGs or TPGs may not be entirely
appropriate and that the concept of context-dependent onco-suppressors may be more extensive than previously
recognised. No significant enrichment of TPGs within regions of frequent genomic gain was seen but TSGs were
significantly enriched within regions of frequent genomic loss. It is suggested that loss of the FHIT gene may be a driver of
NPC tumourigenesis. Notwithstanding the association of TSGs with regions of genomic loss, on a gene by gene basis and
excepting homozygous deletions and high-level amplification, there is very little correlation between chromosomal copy
number aberrations and expression levels of TSGs and TPGs in NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is a highly malignant tumour
of the post-nasal space. It is histologically heterogeneous, often
containing substantial numbers of tumour-infiltrating lymphocytes
[1] and has a curious aetiology with geographical, inherited,
environmental and viral components [2]. Although the incidence
is less than 1 per 100,000 of population per year throughout most
of the world, in parts of Southeast Asia it reaches up to 30 per
100,000. Southern Italy, Greece, Turkey and the Maghreb region
of North Africa have an intermediate incidence of about 8 per
100,000. Heritable cofactors include HLA haplotype and several
genetic susceptibility loci whilst proposed environmental associa-
tions include carcinogenic nitrosamines present in some ethnic
foods of high-and intermediate-risk regions [3,4] and indigenous
plants that contain activators of Epstein-Barr virus (EBV), the viral
component of NPC aetiology [5].
In common with other cancers, NPC tumour cells carry various
chromosomal abnormalities. Studies using conventional and
array-based comparative genomic hybridisation (CGH), (collated
in [6,7]), have localised regions of chromosomal gain and loss.
Although there are several reports of global analysis of gene
expression in NPC [8–15], none of the previous studies has
examined both chromosomal aberrations and gene expression
changes in the same samples. It is believed that in the process of
carcinogenesis, chromosomal gains and losses are linked to the
activation or repression of oncogenes and tumour suppressors. In
this study genetic copy number changes were examined in the
context of alterations in the expression of tumour-promoting and
tumour-suppressing genes (TPGs, TSGs) using a collection of
NPCs that were obtained from high-and intermediate-incidence
areas. Differential expression of a large number of genes that have
previously been suggested as being tumour-promoting or tumour-
suppressing was observed. However the differential regulation of
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many of these was not consistent with their previously proposed
role and reinforces the concept of onco-suppressors and the
context dependence of tumour suppressors and promoters.
Regions of the genome that showed frequent copy number
aberrations were identified. Genes previously reported as tumour
suppressors were significantly associated with regions of frequent
genomic loss whereas putative tumour promoting genes were not
enriched within regions of gain. Counter-intuitively, there was
very little correlation between genomic copy number changes and
levels of expression of TPGs and TSGs.
Results and Discussion
EBV Status and Latent Gene Transcription
The oncogenic human herpesvirus EBV is closely associated
with NPC [5]. To assess the EBV status of the samples used in this
study, the presence of EBV genomes in total cellular DNA and/or
the expression of EBV-specific transcripts was determined (Table 1,
Figure S1). 15 NPC biopsies and cell line C666-1 were examined
for the presence of EBV DNA. All except tumour MMAH were
found to be EBV-positive.
The pattern of EBV gene expression in NPC is referred to as
‘‘Latency II’’ in which only EBNA1, the latent membrane proteins
(LMPs), EBERs and transcripts from the BamHI-A region of the
genome are expressed [5]. In addition, BARF1, a homologue of
the human proto-oncogene c-fms [16], appears to be a latent gene
in NPC [17]. Three of these genes are potential oncogenes in
NPC: LMP1 has been referred to as the main transforming protein
of EBV [5], LMP2 can transform epithelial cells in vitro [18] and
BARF1 has oncogenic properties ([19] and refs therein). RNA
from 12 NPC biopsies, 3 normal samples and cell line C666-1
were assayed for the expression of transcripts for EBNA1 and the
three putative oncoproteins LMP1, LMP2 and BARF1. LMP1,
LMP2 and BARF1 transcripts were detected in 11/13 (85%), 11/
13 (85%) and 9/13 (69%) tumour samples (including C666-1)
respectively. No EBV-specific transcription was detected in the
normal samples suggesting that they are indeed EBV-negative, or
in tumour MMAH, consistent with its apparent EBV DNA-
negativity. Curiously, although other EBV-specific transcripts
were detected in samples MOUZ (shown to be EBV DNA-
positive) and YH8, EBNA1 transcripts were not seen. The basis of
this unexpected result was not pursued but could be due to
sequence variation leading to inefficient pcr primer binding or the
highly repetitive, GC-rich sequences in the EBNA1 mRNA
interfering with the amplification of this message in these two
samples.
Table 1. Samples and their properties.
Sample Designation Origin Patient Ethnicity Gender
EBV
DNA
Status EBNA1 BARF1 LMP1 LMP2
XY5 Guangdong Cantonese M + ND ND ND ND
XY6 Guangdong Cantonese F + + 2 2 2
XY8 Guangdong Cantonese M + + + + +
XY23 Guangdong Cantonese M + ND ND ND ND
HKC1 Hong Kong Cantonese F + ND ND ND ND
HKD1 Hong Kong Cantonese M + + 2 + +
HK4 Hong Kong Cantonese M + + + + +
HK6 Hong Kong Cantonese M + ND ND ND ND
MDIG France Italian M + + + + +
MKAV France Italian M + + + + +
MKEC France Maghreb M + + + + +
MMAH France Maghreb F 2 2 2 2 2
MOUZ Algeria Algerian F + 2 + + +
C666-1 cell line Hong Kong Cantonese M + + + + +
SNP array only
XY16 Guangdong Cantonese M + + + + +
HKC2 Hong Kong Cantonese F + ND ND ND ND
Expression array only
YH7 Guangdong Cantonese F ND + 2 + +
YH8 Guangdong Cantonese M ND 2 + + +
MSTA (normal) Algeria Algerian U ND 2 2 2 2
MBEZ (normal) Algeria Algerian U ND 2 2 2 2
MHAU (normal) France Italian M ND 2 2 2 2
T3 (normal) UK UK U ND ND ND ND ND
The names and properties of the samples are indicated, together with their EBV genome status (EBV DNA) and status of expression of the EBV genes EBNA1, BARF1,
LMP1 and LMP2. Both expression array data and SNP array data were obtained from the first 13 biopsies and cell line C666-1. ‘‘SNP array only’’ indicates that only SNP
array data were obtained from these biopsies whilst ‘‘Expression array only’’ signifies that only expression array data were obtained. U = unknown; ND = not
determined.
doi:10.1371/journal.pone.0041055.t001
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Although tumour MMAH had the histological characteristics of
NPC, was diagnosed as such by at least two pathologists and had
an overall gene expression profile that clustered with EBV-positive
NPCs (data not shown), we were unable to confirm its EBV-
positivity. It is possible that this is a rare case of an EBV-negative,
non-keratinising NPC.
Cellular Gene Expression Analysis
Expression array analysis of cellular gene expression levels was
carried out using RNA from tumour cells of 15 NPC biopsies of
various ethnic origin and NPC cell line C666-1 (hereafter
collectively referred to as ‘‘tumours’’) compared to four samples
of normal epithelia (Table 1). The extent of relatedness of the
overall gene expression profiles between the samples was
examined by correlation analysis. This indicated that the
expression profiles of tumours from different ethnic origins were
closely related to each other but quite distinct from that of the
normal samples.
Comparison of the gene expression of tumour cells versus normal
controls also revealed that the Wnt, TGF-beta and Hedgehog
signalling pathways were dysregulated. These observations agree
with and extend those in earlier NPC gene expression studies
[8,9,10] and will be presented in full elsewhere. Additional genome-
wide expression studies of NPC have focused attention on other
signalling pathways [14], MHC class I [10], cell cycle regulation
[15], DNA repair and nitrosamine metabolism [9] or a single TSG
[13]. The current analysis concentrates on genes that have been
proposed to have a role in oncogenesis (e.g. oncogenes, tumour
suppressor genes) and identifies a number of such differentially
expressed genes that have not previously been implicated in NPC.
Some of these have been identified but not discussed in the earlier
studies. They are noted in Tables S1 and S2.
Differential Expression of Tumour-related Genes
The expression array data were examined for differential
expression of 1049 a priori determined, tumour-related genes.
These genes comprised 309 putative tumour-promoting genes
(TPGs), (including oncogenes, apoptosis/anoikis-suppressing and
metastasis-promoting genes) and 740 putative tumour suppressors
(TSGs). Expression changes in a number of differentially expressed
genes representing each of the above categories were confirmed at
the protein level by immunohistochemistry (IHC). In a few cases
the same samples that were used for array analysis were available
but usually, because of sample limitations, an NPC tissue array
constructed from a different sample set was used. The IHC
validation results are presented in Figure 1 and Tables S1 and S2.
Upregulated Genes
From the a priori list of 1049 putative tumour-related genes, 346
were found to be upregulated more than twofold in at least four
(25%) tumours and include 124 that have previously been shown
to be upregulated in NPC or implicated in its pathogenesis (Table
S1). The mean number of TPGs upregulated in each sample was
89 (range 36–115). The top 48 putative TPGs that were
upregulated in 12 or more (75%) samples are listed in Table 2.
Most of these have not previously been implicated in NPC.
Frozen sections taken from biopsies that were used for the array
analysis were used in IHC to confirm upregulation of the
oncogene EZH2 (Figure 1A). EZH2 expression was also validated
using an NPC tissue array, along with the TPG SKIL (Figure 1B).
NPC is highly metastatic, with 75% of metastases occurring in
bone. Upregulated, bone metastasis-associated genes include NOV
and TNFRSF11A which were upregulated in 10 and 5 tumours,
respectively (Table S1). The metastasis-associated gene osteopontin
(SPP1), a target of aberrant Wnt signalling that has been implicated
in NPC was upregulated in 11 tumours (Table S1). Immunohisto-
chemical staining validated upregulation of the metastasis-associat-
ed, TGFb pathway target, TGFBI (Figure 1G).
Upregulated antiapoptotic genes include the NPC-associated
genes BIRC3, BCL2 and CLDN1 which is also a target of the Wnt
signalling pathway. Upregulation of the anti-apoptotic gene
TNFAIP3 was confirmed at the protein level (Figure 1G).
Anoikis is a form of apoptosis that is induced by loss of, or
inappropriate, cell adhesion. A variety of genes, including the Wnt
pathway-associated CTNNB1 (Figure 1G), that have been impli-
cated in mechanisms of anoikis resistance were found to be
upregulated in many tumour samples.
Downregulated Genes
140 genes from the a priori list of tumour-related genes were
downregulated more than twofold in four or more tumours and
include 40 that have been independently reported to be
downregulated in NPC (Table S2). 115 of these genes have been
proposed to be TSGs in other contexts, including 7 in NPC. The
mean number of TSGs downregulated in each tumour was 76
(range 56–93). 52 putative TSGs, the majority of which have not
been previously implicated in NPC, were downregulated in 12 or
more (75%) samples (Table 3).
Confirmation of downregulation of the TSGs ANXA1, LCN2,
KLF4, CLU and MSH3 was obtained by immunohistochemistry
(Figure 1D–G). Downregulation of ITGA2, which has been
associated with tumour progression, was also verified. Although
the expression studies found 115 previously characterised TSGs to
be downregulated, even this number is an underestimate. Several
NPC-associated TSGs, including RASSF1 and PTPRG [20,21]
were expressed at low levels in both normal and tumour samples
and were called ‘‘absent’’ by the analysis software. Thus relative
expression levels could not be determined and these genes were
not included in the list of downregulated genes. Similarly, other
well-known NPC TSGs e.g. CDKN2A [22], ATM [13] and
ZMYND10 [23] were called ‘‘present’’ in only 3 normal samples
and therefore did not fulfil the criteria to be designated as
downregulated.
Potential Onco-suppressor Genes
Examination of the expression data for the behaviour of specific
genes in single tumours reinforces the concept of the individuality
of each tumour. Although some TPGs and TSGs (e.g. BCL2,
VWA5A) appear to be universally differentially expressed, the
majority seem to be important in only a fraction of cases. In
addition, although many putative TSGs and TPGs were
respectively downregulated or upregulated in the tumour samples
relative to normal tissue, a substantial number exhibited differen-
tial expression in the ‘‘wrong’’ direction. Previous studies have
proposed that 208 of the 346 upregulated genes act as TSGs in
other types of cancer. Other, independent studies have confirmed
the upregulation of 127 (61%) of these genes in NPC or other
tumour types (Table S1). Examples are ROBO1, LATS2 and
SPARC, which are tumour suppressive in several cancers [24–26]
but upregulated and associated with tumour progression, metas-
tasis and decreased survival in NPC [27–29]. Others include
several Wnt-and TGFb-pathway-associated genes and MNX1,
CLDN1, ATF2, SIRT1, PTPN13 and E2F1 which have been
discussed as possessing both tumour-promoting and tumour-
suppressing properties (onco-suppressors) [30–35]. This suggests
that, at least at the stage of tumour development when the samples
were taken, these genes do not act as TSGs in NPC.
Copy Number and Gene Expression Changes in NPC
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Similarly, 35 of the 115 downregulated, putative TSGs have
been found to be upregulated in other tumour types. 6 of these
(CLU, LCN2, KLF4, KLF5, KLF6, SLC9A3R1) have been discussed
as onco-suppressors [36–41].
Of the 486 putative TPGs and TSGs that were identified as
being differentially expressed, 273 (56%) appear to be both
upregulated and downregulated in cancer. This is consistent with
the increasing awareness that there exists a population of proteins
that can act as either tumour suppressors or tumour promoters
depending on cellular context such as tumour type, stage of
tumour development or subcellular location. Similarly, the TGFb
signalling pathway has been shown to be either tumour promoting
or suppressing [42]. We and others have shown this pathway to be
dysregulated in NPC and several TGFb pathway-associated
putative TSGs show differential expression in the opposite
direction to that expected from some literature reports. In this
context, enhanced expression was observed of PMEPA1, which
recently has been shown to be able to act as a molecular switch
that converts TGFb from a tumour suppressor to a tumour
promoter [43].
Some putative TSGs and TPGs appeared to be upregulated in
some samples whilst downregulated in others. Two such genes, the
Wnt pathway-associated genes WNT5A and CD44, both of which
on array analysis could not be regarded as predominantly up-or
down-regulated, were examined by IHC (Figure 1C, G). WNT5A,
which has been described as being either tumour promoting or
suppressing [44], was upregulated at the protein level in 10/23
samples and unchanged in the remainder whilst CD44 protein
expression was increased in 6/12, reduced in 2/12 and unchanged
in the remaining 4 (Figure 1G). Similarly, the putative tumour
suppressor protein, E-cadherin (CDH1) has been found to be both
upregulated and downregulated in NPC [45]. On our expression
arrays it appeared to be upregulated in 4 samples, downregulated
in 3 and unchanged in 9. Whether such instances represent the
particular gene product acting as a tumour suppressor in some
cases, whilst being a promoter in others, is currently unknown.
Functional characterisation of putative TSGs or oncogenes
using cell lines or animal models reveals dramatic effects on cell
growth in response to the perturbation of expression of just a single
TSG or oncogene (e.g. [20,21]). Considering these data alongside
the current observations that reveal dysregulation of large
numbers of TSGs and TPGs per tumour, emphasises the
magnitude of the loss of proliferative control in NPC and begs
the question as to how many-or how few–aberrantly regulated
TSGs and TPGs are required for tumourigenesis. It will be
important to perform functional studies, in the appropriate
context, of the putative TSGs and TPGs identified here and to
confirm the apparent dual role of the putative onco-suppressor
genes.
Copy Number Changes in NPC Tumour Cells
Analysis of amplified DNA from the C666-1 cell line and from
15 NPC biopsies revealed that all tumour samples showed
extensive chromosomal copy number aberrations. The principal
regions of loss were within 1p, 3p, 5q, 9p, 9q, 11q, 13, 14q, 16 and
21q whilst 8q, 12p and 12q showed the most significant gains
(Figure 2A). These results are in broad agreement with data
obtained in several previous studies [6,7]. In particular, copy loss
at 3p21.3, 9p21.3 and 11q23.3 was observed in 14/16 (88%), 9/16
(56%) and 11/16 (69%) of samples, respectively. The amplicon at
12p13.3 that was recently identified by Or et al [46] in 51% of
primary tumours exhibited copy number gain in 4 (25%) tumours.
Less consistent with earlier data, the 11q13.3 locus at which Hui
et al [47] found copy number gain in 62% of primary NPCs
showed gain in only 1 sample (6%).
TSGs are Enriched within Regions of Loss
After segmentation, copy number information was available for
21204 named genes, of which about 3.4% (714/21204) are
putative TSGs. It was first asked for each sample whether TSGs
are more frequently found in the group of genes showing reduced
copy number. 12/16 samples showed a significant enrichment
(p,0.05). The enrichment of TSGs in the deleted genes was
calculated with different frequency cut-off values. 4.2% of genes
deleted in 5 or more samples were TSGs, increasing progressively
to 44% within those deleted in 14 or more samples (Table 4). The
TSGs enriched within genomic segments deleted in 12 or more
(75%) samples are listed in Table 4.
Although TPGs were found within deleted genes, they were
significantly enriched in only one sample (C666-1).
About 1.4% (299/21204) of named genes were TPGs. There
was no significant enrichment of TPGs within copy-gain genes in
any sample. The enrichment of TPGs in the copy-gain genes was
also calculated with different frequency cut-off values. TPGs were
not significantly enriched in the genes showing gain of copy
number (Table S3).
Although TSGs were present within the group of genes showing
copy number gain, they were not significantly enriched in any of
the samples.
Determination of Significant Regions of Copy Number
Change
To search for non-random copy number aberrations that may
play a role in tumourigenesis, a standard analysis of Genomic
Identification of Significant Targets in Cancer (GISTIC) [48] was
performed. In the deletion peaks, which include the well-known
TSG-containing loci at 3p21.31 and 9p21.3, TSGs were
significantly (p = 4.1461026) enriched to 6.2% (62/993). Impor-
tantly, 42 deletion peaks contained a total of 62 TSGs (Table S4).
Of these 62 deleted TSGs, 16 were downregulated as determined
by expression array analysis. The downregulation of one of these,
CLU, was verified at the protein level by IHC (Figure 1G).
Additionally, genes that have been implicated as NPC TSGs were
found within these deletion peaks. These genes include CDKN2A,
ZMYND10, RASSF1, NDRG1, TACC2 and CACNA2D2 (Table S4).
Conversely, the expression array data indicated that 16 of these
deletion peak-associated putative TSGs appeared to be upregu-
lated. Independent studies also suggest that of these, CDH1,
COL4A1, BUB1B, RUNX3 and SOCS1 are upregulated in NPC
(Table S2) whilst the expression of a further 5 has been reported to
be enhanced in other cancers.
Figure 1. Immunohistochemical validation of differential regulation. Panels A–F show normal epithelium on the left and tumour tissue on
the right. Panel A uses frozen sections from the same samples that were used in the array analysis (MHAU; normal epithelium: XY23; NPC), Panels B–F
are paired specimens from the NPC tissue array. A–C: the upregulated genes EZH2, SKIL and CD44. D–F: the downregulated genes ANXA1, LCN2 and
MSH3. Panel G summarises all the tissue array staining. The Y axis shows the log2 value of the ratio of the paired tumour:normal IHC scores. Some IHC
scores were zero resulting in log2 ratio values of plus or minus infinity. For convenience, these are represented as 4 or24 on the figure. Except for JAK
and CD44, p values were less then 0.05. Individual p values are listed in Tables S1 and S2.
doi:10.1371/journal.pone.0041055.g001
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Table 2. A priori defined, putative tumour promoting genes upregulated more than twofold in at least 12 (75%) samples.
Gene Symbol Description No. q No. NC No. Q
TFRC transferrin receptor (p90, CD71) 16 0 0
ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 16 0 0
BCL2 B-cell CLL/lymphoma 2 16 0 0
ROBO1 roundabout, axon guidance receptor, homolog 1 (Drosophila) 16 0 0
NCOA3 nuclear receptor coactivator 3 15 1 0
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 15 1 0
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 15 1 0
RAN RAN, member RAS oncogene family 14 2 0
EIF4A2 eukaryotic translation initiation factor 4A, isoform 2 14 2 0
FUS fusion (involved in t(12;16) in malignant liposarcoma) 14 2 0
TPR translocated promoter region (to activated MET oncogene) 14 1 1
JAK2 Janus kinase 2 (a protein tyrosine kinase) 14 2 0
RHEB Ras homolog enriched in brain 14 2 0
PDE4DIP phosphodiesterase 4D interacting protein (myomegalin) 14 2 0
RAB18 RAB18, member RAS oncogene family 14 2 0
GNA13 guanine nucleotide binding protein (G protein), alpha 13 14 2 0
ASAP1 development and differentiation enhancing factor 1 14 2 0
XIAP baculoviral IAP repeat-containing 4 14 2 0
BIRC3 baculoviral IAP repeat-containing 3 14 2 0
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 14 2 0
RBM15 RNA binding motif protein 15 13 3 0
RAP1B RAP1B, member of RAS oncogene family 13 3 0
DEK DEK oncogene (DNA binding) 13 3 0
EZH2 enhancer of zeste homolog 2 (Drosophila) 13 3 0
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 13 3 0
TOP1 topoisomerase (DNA) I 13 2 1
WHSC1 Wolf-Hirschhorn syndrome candidate 1 13 3 0
RAB28 RAB28, member RAS oncogene family 13 3 0
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 13 3 0
RPL22 ribosomal protein L22 13 3 0
RAP2C RAP2C, member of RAS oncogene family 13 3 0
ECT2 epithelial cell transforming sequence 2 oncogene 13 3 0
TPM3 tropomyosin 3 13 3 0
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 13 3 0
KAT6A K(lysine) acetyltransferase 6A 13 3 0
KDSR 3-ketodihydrosphingosine reductase 13 3 0
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 13 3 0
CTNNB1 catenin (cadherin-associated protein), beta 1, 88 kDa 13 3 0
ATF2 activating transcription factor 2 13 3 0
CLTC clathrin, heavy chain (Hc) 12 3 1
JUN jun oncogene 12 4 0
RAP1A RAP1A, member of RAS oncogene family 12 4 0
TRIM24 tripartite motif-containing 24 12 4 0
CIITA class II, major histocompatibility complex, transactivator 12 4 0
PSIP1 PC4 and SFRS1 interacting protein 1 12 4 0
PICALM phosphatidylinositol binding clathrin assembly protein 12 4 0
SKIL SKI-like oncogene 12 4 0
ITGB6 integrin, beta 6 12 4 0
Q = downregulated, q = upregulated, NC = no change. Further information can be found in Table S1.
doi:10.1371/journal.pone.0041055.t002
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Table 3. A priori defined, putative tumour suppressor genes downregulated more than twofold in at least 12 (75%) samples.
Gene Symbol Description No. Q No. NC No. q
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 16 0 0
CLCA2 chloride channel, calcium activated, family member 2 16 0 0
CLU clusterin 16 0 0
DUOX2 dual oxidase 2 16 0 0
EHF ets homologous factor 16 0 0
EPAS1 endothelial PAS domain protein 1 16 0 0
H19 H19, imprinted maternally expressed untranslated mRNA 16 0 0
JUP junction plakoglobin 16 0 0
KLK11 kallikrein-related peptidase 11 16 0 0
LCN2 lipocalin 2 (oncogene 24p3) 16 0 0
MSMB microseminoprotein, beta– 16 0 0
MSRA methionine sulfoxide reductase A 16 0 0
PER2 period homolog 2 (Drosophila) 16 0 0
S100A2 S100 calcium binding protein A2 16 0 0
SOX7 SRY (sex determining region Y)-box 7 16 0 0
VWA5A von Willebrand factor A domain containing 5A 16 0 0
ZNF185 zinc finger protein 185 (LIM domain) 16 0 0
RAB25 RAB25, member RAS oncogene family 16 0 0
SFN stratifin 15 1 0
ANXA1 annexin A1 15 1 0
DLG1 discs, large homolog 1 (Drosophila) 15 1 0
DUOX1 dual oxidase 1 15 1 0
GJB2 gap junction protein, beta 2, 26 kDa 15 1 0
GPX3 glutathione peroxidase 3 (plasma) 15 1 0
KLF5 Kruppel-like factor 5 (intestinal) 15 1 0
SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13 15 1 0
TACC2 transforming, acidic coiled-coil containing protein 2 15 1 0
ING2 inhibitor of growth family, member 2 14 2 0
BRD7 bromodomain containing 7 14 2 0
IGFBP5 insulin-like growth factor binding protein 5 14 2 0
PERP PERP, TP53 apoptosis effector 14 1 1
SDHC succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa 14 2 0
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 14 1 1
SLC9A3R1 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 14 2 0
CSK c-src tyrosine kinase 13 3 0
LLGL2 lethal giant larvae homolog 2 (Drosophila) 13 3 0
RARB retinoic acid receptor, beta 13 3 0
RPS6KA2 ribosomal protein S6 kinase, 90 kDa, polypeptide 2 13 3 0
SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 13 3 0
CBFA2T3 core-binding factor, runt domain, alpha subunit 2; translocated to, 3 12 4 0
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 12 4 0
CXCL14 chemokine (C-X-C motif) ligand 14 12 2 2
GLTSCR2 glioma tumor suppressor candidate region gene 2 12 4 0
HRASLS HRAS-like suppressor 12 3 1
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 12 3 1
PPP1R13B protein phosphatase 1, regulatory (inhibitor) subunit 13B 12 4 0
PRDX2 peroxiredoxin 2 12 4 0
PYCARD PYD and CARD domain containing 12 4 0
TMSB10 thymosin, beta 10 12 4 0
Copy Number and Gene Expression Changes in NPC
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Figure 2. Chromosomal copy number changes. Panel A shows the major regions of copy number gain (red) or loss (blue) across the genome.
The Y axis shows the number of cases (out of 16) at which a region was changed. Chromosomes are ordered from left to right as indicated. Panels B–
D show traces of the log2 ratio of the copy number of DNA from the tumour samples compared to the normal controls. B: the homozygous deletion
at the FHIT locus in C666-1; C: a hemizygous deletion in C666-1 and a homozygous deletion in tumour XY5, both at 6q22.33; D: homozygous
deletions encompassing the CDKN2B locus in tumours MMAH, XY5, XY8 and HKC1. Tumour MMAH also shows a 600 Kb homozygous deletion at
9p24.1 containing the NFIB gene. The sizes of the discrete aberrations are indicated.
doi:10.1371/journal.pone.0041055.g002
Table 3. Cont.
Gene Symbol Description No. Q No. NC No. q
VTA1 Vps20-associated 1 homolog (S. cerevisiae) 12 4 0
WASL Wiskott-Aldrich syndrome-like 12 4 0
Q = downregulated, q = upregulated, NC = no change. Further information can be found in Table S2.
doi:10.1371/journal.pone.0041055.t003
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177 peaks of copy gain were identified. In these peaks, 1.2% (6/
515) of genes are TPGs, which are not significantly (p = 0.73)
enriched. 6 peaks of copy number gain contained 6 TPGs (Table
S5), of which 4 (ERBB4, RAB21, PSIP1, ZNF384) appeared to be
upregulated (Table S1).
The observation of upregulated expression of some of the TSGs that
were associated with frequently deleted genomic segments could signify
that these putative TSGs, if indeed they do act as such in NPC, may be
active as suppressors at an early stage of carcinogenesis but later
convert to a tumour-promoting role. However it is also possible that, in
keeping with the two-hit hypothesis, the protein products of these
transcripts may be non-functional or absent due to mutation.
Homozygous Deletions
It is believed that homozygous deletions (HD) in tumours are
particularly noteworthy for their potential to encompass tumour
suppressor gene loci [49]. 205 genes appeared to be homozygously
deleted. 55 of these were within deleted segments validated by q-pcr
(Table S6). 56% (9/16) of the NPC samples have homozygously
deleted TSGs including FHIT and CDKN2B, both of which have been
implicated in NPC [50,51]. The enrichment of TSGs in the
homozygously deleted genes was calculated with different frequency
cut-off values (Table S7). TSGs were shown to be significantly enriched
in homozygously deleted genes. However, increasing the cut-off
frequency does not significantly increase the enrichment of TSGs.
In agreement with previous observations in a variety of tumours
including NPC, [51] the TSG CDKN2B was a frequent target of
HD (Figure 2D). Additionally, it was striking that in one sample
the only genetic loss within chromosome 3p was a discrete
homozygous deletion of the FHIT gene (Figure 2). This locus was
hemizygously deleted in a further 11 tumours. Studies using
knockout mice revealed that animals in which the FHIT gene was
hemizygously or homozygously deleted were ‘‘exquisitely sensi-
tive’’ to nitrosamine-mediated carcinogenesis [52]. These obser-
vations together with those showing that loss of chromosome 3p
occurs in ‘‘almost all’’ [53] cases of primary NPC and in
premalignant lesions [54] together with epidemiological evidence
that dietary nitrosamines predispose to the development of NPC
[2–4] suggest that hemizygous or homozygous loss of FHIT may
be a driver of NPC tumourigenesis.
Table 4. Enrichment of TSGs with increasing frequency of genomic deletion.









P value of binomial
test Deleted TSGs
5 or more 5543 233 4.2% 4.861024
6 or more 4045 172 4.3% 1.561023
7 or more 2770 132 4.8% 6.861025
8 or more 1966 101 5.1% 3.061025
9 or more 1386 80 5.8% 3.861026
10 or more 975 57 5.9% 6.061025
11 or more 553 36 6.5% 1.761024
12 or more 161 20 12.4% 6.061027 FAM107A, FHIT, HHATL, PCBP4, RBM5, RPS14 and the 14
TSGs below
13 or more 39 14 35.9% 1.6610211 LRIG1, POU2F3, PRKCD, and the 11 TSGs below
14 or more 25 11 44.0% 1.8610210 CACNA2D2, CYB561D2, HYAL1,HYAL2, NAT6, NPRL2,
RASSF1, SEMA3B, SEMA3F, TUSC2, ZMYND10
The frequency of TSGs within deleted genes increases progressively as the common deleted region(s) are found in increasing numbers of samples. The TSGs found in
the most frequently deleted regions are listed in the column on the right.
doi:10.1371/journal.pone.0041055.t004
Figure 3. The 8p11.21 amplified region of tumour HKD1. A.
Trace of the log2 ratio of the copy number of DNA from the tumour
sample compared to the normal controls. The 2.5 Mb amplification is
indicated. B. Heat map of the relative expression levels of the genes
found within the amplified region. The samples appear in columns and
the individual genes within the amplified region form the rows. High
level expression is represented by the intensity of red and low level by
blue. The brackets at the bottom indicate tumour samples with
genome copy numbers of 2 or 3 within this region.
doi:10.1371/journal.pone.0041055.g003
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Amplification within Chromosome 8 is Associated with
Increased Gene Expression
The only example of an amplification (5 or more copies) that
was found in this sample set is a 2.5 Mb segment in tumour
HKD1 (Figure 3). The array data suggested that this region
contained 11.6 DNA copies whilst q-PCR analysis gave a value of
8.7 (Table S6). Expression arrays showed the mRNA levels of the
majority of genes throughout this region, including the putative
oncogene KAT6A, to be substantially upregulated in the amplified
sample but relatively unchanged in samples with two or three
copies (Figure 3). Relative to the mean of the normal samples, the
expression of KAT6A in tumour HKD1 was upregulated 31-fold
and was up more than twofold in 12 other tumours (Table 2).
Interestingly, this amplified segment corresponds to the A4
amplicon defined in breast cancer where overexpression of the
genes KAT6A and AP3M2 was most significant [55]. However, the
functional identity of any oncogene(s) in this region remains to be
established.
Expression Levels of TPGs and TSGs are Poorly Correlated
with DNA Copy Number
It is frequently surmised that regions of chromosomal loss are
likely to harbour (downregulated) tumour suppressor genes whilst
regions of gain may be associated with overexpression of growth
promoting genes. The frequency of putative TSGs encoded within
deleted segments of the genome increased along with the
proportion of samples containing a given deletion. This finding
is in keeping with the theory of genomic loss being at least part of
the mechanism of inactivation of TSGs in the process of
tumourigenesis. Whilst the concept that gene expression changes
in tumours are directly related to genomic copy number may be
mechanistically appealing, in general, expression of the putative
TSGs and TPGs in the NPC samples was not well-correlated with
copy number. Expression and copy number data were available
for 478 of them (Tables S1 and S2). Analysis of the level of gene
expression versus DNA copy number on a case by case basis
revealed that 469 of the 478 TPGs and TSGs (98.1%) had a
Spearman’s correlation coefficient of less than 0.65.
This finding is similar to other studies, e.g. in glioma [56], which
found that only a few genes within the total transcriptome showed
good correlation between copy number and expression. It is
increasingly apparent that reduction in expression of TSGs seems
mostly to be achieved by epigenetic mechanisms such as promoter
hypermethylation and histone deacetylation [57,58] whilst upre-
gulation of gene expression can be achieved by a variety of
transcriptional regulatory mechanisms.
Conclusions
This work is focussed on potential tumour-promoter and-
suppressor genes in NPC. It shows that the EBV-encoded EBNA1
protein, and the three putative viral oncogenes LMP1, LMP2 and
BARF1 are expressed in the majority of cases that were examined
and also identifies a large number of potential cellular TPGs and
TSGs, many of which have not previously been associated with
NPC. A number of these were found to be components or targets of
the Wnt and TGF-beta signalling pathways, providing evidence for
dysregulation of these pathways in NPC. It shows that genes that
have been described as potential tumour promoting genes are not
significantly associated with genomic regions exhibiting gain of copy
number. On the contrary, genes described as TSGs are significantly
enriched within genomic regions that are frequently deleted even
though the expression of some of these genes within hemizygous
deletions appears to be upregulated. It is suggested that loss at the
FHIT locus may be a driver of NPC tumourigenesis. Very little
correlation is observed between the level of TPG and TSG
expression and genomic copy number except for loss of expression
in homozygous deletions and one highly amplified segment which
shows enhanced gene expression. Individual NPC tumours each
express a large number of dysregulated, putative, tumour-suppress-
ing and tumour-promoting genes but almost 60% of these genes can
be either upregulated or downregulated in different types of tumour.
This suggests that the simplistic classification of genes as TSGs or
TPGs may not be entirely appropriate and that the concept of onco-
suppressors may be more extensive than previously recognised.
Materials and Methods
Ethics Statement
This study was approved by the South Birmingham Research
Ethics Committee (Reference 09/H1207/95). All samples were
anonymous.
The Paris samples were obtained between September 1992 and
June 1995 using verbal consent in accordance with protocols (for
the use of surgical tissues and medical records) previously
approved by the local human studies committee.
The samples from Zhanjiang were obtained between 2001 and
2005 following local procedures applicable at that time.
The Hong Kong samples were obtained using verbal consent
for donation of normal and tumour tissues for genetic research
following a procedure approved by The Hong Kong University
and Hospital Authority (Hong Kong West) Institutional Review
Board (Reference UW 06-149 T/1174).
The samples from Oran, Algeria were obtained under
authorisation from the senior medical management of the hospital
and with the patients’ written consent.
One control sample came from a frozen section of a tonsil
obtained, with informed written consent and ethical approval
(South Birmingham Research Ethics Committee Reference 06/
Q2702/50).
DNA from five individuals with normal DNA copy number was
from blood samples taken with informed written consent and
ethical approval (Cambridgeshire 3 Research Ethics Committee
(Reference 09/H0306/79)). These samples had already been
subjected to array-based DNA copy number analysis in the
original study.
NPC Biopsies
Snap-frozen biopsies of NPC were obtained from the Associated
Hospitals of Guangdong Medical College, China; Queen Mary
Hospital, Hong Kong; Institut Gustave Roussy, France and Oran
Hospital, Algeria. All samples had concurrent formalin fixed
material which was used and retained by local pathologists to
diagnose the cases as NPC (undifferentiated, non-keratinising
carcinoma). This diagnosis was confirmed by one of us (XC) on
sections taken from the frozen tissue used in the analysis. Except
for gender and ethnic origin, no further information was available.
Samples were transported on dry ice and stored in liquid nitrogen
until used. Tumour samples for analysis were selected on the basis
of their having well-defined islands of tumour cells with minimal
numbers of infiltrating lymphocytes. Three biopsies that did not
contain any tumour tissue had areas of normal epithelium that
were used as a source of control material for the expression studies.
A fourth normal control came from a frozen section of a tonsil
obtained from a UK patient. The samples and their origins are
listed in Table 1. Samples were tested for EBV DNA-positivity by
PCR on extracted DNA [59] and for the expression of EBV
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encoded genes by RT-PCR as described [60] using the primers
listed in Table S8.
NPC Tissue Array
An NPC tissue array consisting of paired samples containing
both NPC tumour and adjacent nasopharyngeal mucosa was
constructed using formalin-fixed, paraffin-embedded samples from
the archives of the Pathology Department, Sun Yat-Sen Univer-
sity, Guangzhou [61]. EBER in situ hybridisation verified that all
tumours were EBV-positive whereas the corresponding normal
cells were negative.
Immunohistochemistry
In a few cases the same samples that were used for array analysis
were available but usually, because of sample limitations, an NPC
tissue array constructed from a different sample set was used.
FFPE tissue array sections were deparaffinised in xylene and
rehydrated through ethanol to distilled water, then incubated with
3% hydrogen peroxide for 15 minutes to quench endogenous
peroxidase. Antigen retrieval was performed using the agitated low
temperature epitope retrieval method [62], or by heating in low
pH retrieval buffer (Vector Laboratories) for 20 minutes at 880 W
in a microwave oven. Sections were rinsed with PBS then
incubated with primary antibody for one hour at room temper-
ature. After three brief washes with PBS/Tween, slides were
treated with a peroxidase-based secondary antibody (Dako
EnVisionTM Detection System, Denmark) for 30 minutes at room
temperature. The final peroxidase-labelled complex was visualised
using diaminobenzidine. The tissue sections were counterstained
with hematoxylin, dehydrated, and mounted with coverslips.
For frozen tissue, 8 micron cryosections were cut, air dried and
fixed in 10% formalin for 20 minutes. The sections were then
incubated in 3% hydrogen peroxide for 15 minutes, followed by
antigen retrieval in low pH buffer for 20 minutes as above. The
subsequent procedures were as described for FFPE sections.
The antibodies used in IHC are listed in Table S9.
IHC Scoring
A semiquantitative scoring system was used to evaluate IHC
staining. Scores (values 0–9) were obtained by multiplying staining
intensity (negative = 0, weak = 1, moderate = 2, or strong = 3) by
the proportion of positive cells (#30% = 1, 30%–70% = 2,
.70% = 3).
Cell Culture
The EBV-positive NPC cell line C666-1 [63] was obtained from
the late Dolly Huang. Cells were cultured on fibronectin-coated
dishes to ensure adherent cell growth. The EBV-positive B-
lymphoblastoid cell line X50-7 [64] was provided by George
Miller. Both C666-1 and X50/7 were cultured in RPMI medium
1640 supplemented with 10% FCS, 2 mM L-glutamine, and 1%
penicillin–streptomycin solution (Sigma-Aldrich).
Microdissection, Nucleic Acid Extraction and
Amplification
8 micron cryosections were transferred onto PALM membrane
slides (P.A.L.M. Microlaser Technologies) and air dried on ice for
about 1 minute. Slides were immersed for 2 minutes in cold 75%
ethanol, tapped dry and stained for 30 seconds in cold haema-
toxylin and eosin (9:1) containing 1% NucleoGuard (AmpTec,
Hamburg). Excess stain was tapped off and slides were washed in
cold nuclease-free water for 30 seconds, cold 75% ethanol for
1 minute, cold 100% ethanol for 1 minute then air dried. Cells for
analysis were excised by laser microdissection and pressure
catapulting using a PALM MicroBeam instrument and caught
on PALM Adhesive Caps. A minimum of 200,000 mm2 of tissue
was collected for each DNA or RNA extraction. RNA was
extracted by adding 100 ml of RLT buffer (Qiagen) supplemented
with 1 ml of N-carrier (AmpTec) and 1 ml of NucleoGuard
followed by incubation at room temperature for 15 minutes.
Extracted RNA was cleaned up using a Qiagen RNeasy mini kit,
including the on-column DNase step as per the manufacturer’s
instructions. The eluted RNA was collected by ethanol precipi-
tation in the presence of 1 ml P-carrier (AmpTec) and washed
twice with 80% ethanol. After checking the quality using the pico
assay on an Agilent Bioanalyser, RNA was subjected to three
rounds of amplification followed by biotin labelling using an
ExpressArt TR Nano amplification kit (AmpTec) and an
Affymetrix IVT labelling kit as previously described [65].
Total RNA was extracted from C666-1 cells as described [65] and
cleaned up as above. 20 ng was amplified and labelled as above.
DNA was extracted from microdissected cells by adding 100 ml
of lysis buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1%
Tween 20, 0.4 mg/ml proteinase K (Qiagen) to the tube
containing the captured cells and incubating inverted for 3 hr at
55uC then 5 min at 95uC. 2 ml of linear polyacrylamide solution
(GenElute, Sigma) were added and DNA was recovered by
ethanol precipitation. The pellet was washed with 70% ethanol
and air dried. The precipitated DNA was subject to whole genome
amplification using a Genomiphi kit (GE Healthcare) according to
the manufacturer’s instructions.
DNA was extracted from C666-1 and X50-7 cells using a
DNeasy kit (Qiagen) according to the manufacturer’s instructions.
DNA samples prepared from blood samples, taken from five
individuals with normal DNA copy number, were a kind gift from
Dr Tessa Webb.
Hybridisation to Affymetrix Arrays
Biotinylated RNA was fragmented and hybridised to Affymetrix
Human Genome U133Plus2 Arrays according to the Affymetrix
protocol. C666 DNA and DNA amplified from cryosections were
subjected to the Mapping 500 K Assay Protocol (Affymetrix)
protocol.
All arrays were washed and stained on an Affymetrix FS450
fluidics station then scanned using an Affymetrix GeneChip 3000
7G scanner as per Affymetrix procedures. GCOS software
(Affymetrix) was used for instrument control and data acquisition.
Validation of Copy Number Analysis on Amplified DNA
The C666-1 cell line, an NPC-derived line that uniquely
maintains the EBV genome in long term culture, was used to
validate the SNP array copy number analysis and DNA
amplification protocols. Amplified and unamplified C666-1 DNAs
were analysed on 500 K arrays and showed a high degree of
concordance. Genes identified as deleted using the amplified
C666-1 DNA were over 99% identical with those identified using
the unamplified DNA. Genes identified as being within regions of
gain in the amplified C666-1 DNA were over 97% identical with
those found using the unamplified DNA. In a total of 21204
named genes on somatic chromosomes, 99.53% (21105) were
concordantly called deleted, gained or normal in the amplified and
unamplified C666-1 samples.
Array Data Analysis
Genotype analysis was performed using Affymetrix Genotyping
Console version 4.0 with the default settings. QC call rates of the 44
arrays ranged from 81.7% to 95.2%. The array signal intensity CEL
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files of the NPC and amplified normal copy number control samples
as well as 127 hapmap female samples (http://www.hapmap.org/
downloads/raw_data/affy500k/) were analyzed together using
dChip [66] with invariant set normalization and the PM/MM
difference model. SNP-level raw log2 ratios relative to the average of
the hapmap samples were exported from dChip and further
analysed using R (http://www.r-project.org/). For the correction
of amplification effects, SNP-level raw log2 ratios of the amplified
samples were subtracted by the median log2 ratios of the
corresponding probe of the 5 amplified normal copy number
controls. Raw log2 ratios of each array were then centred to a
median of zero. Raw log2 ratios of each sample on both Sty and Nsp
arrays were combined and segmented using a faster circular binary
segmentation algorithm [67]. Segment means were assigned to
genes within the segments for each sample using the CNTools
package of Bioconductor (http://www.bioconductor.org). SNP,
gene, and cytogenetic band locations are based on the hg18 genome
build. Deletion threshold was set to log2 (1.5/2) and amplification
threshold to log2 (2.5/2). A gene is considered deleted (amplified) if
its assigned log2 ratio is less (greater) than the deletion (amplification)
threshold. In the amplified normal samples, less than 0.19% genes
have log2 ratio less than the deletion threshold and less than 0.1%
genes greater than the amplification threshold.
Expression array data were analysed with GCOS using the
default settings except that the target signal was set to 100.
Comparisons based on mean expression levels in cancers and
controls will fail to detect changes that are restricted to only a few
tumours. Therefore the number of tumours in which genes of
interest were up-regulated or down-regulated is reported using the
following rules. A gene was considered upregulated if its GCOS
call in a tumour was ‘‘present’’ and its normalised expression level
was greater than twice the mean of the normal samples; and
downregulated if it was called ‘‘present’’ in all 4 of the normal
samples and its expression level in the tumour was more than
twofold less than the mean of the normals. A gene was considered
to be unchanged if it met none of these criteria. Application of the
above rules to only the normal samples estimated the false positive
rate for upregulated genes to be 3.2% whilst that for downreg-
ulated genes was 8.7%.
A gene expression heatmap was generated using dChip [66].
Log ratio plots were produced using IGB [68].
An extensive literature search for tumour suppressor genes
produced a list of 740 previously identified putative TSGs. A list of
309 potential tumour promoting genes was compiled from genes
designated ‘‘oncogene’’ in their NCBI gene title, from the list in
[69] and from individual instances in the literature.
Determination of DNA Copy Number Using Quantitative
PCR (q-PCR) Assays
Genomic copy number predicted by the SNP array analysis
software was verified by q-PCR using the combinations of forward
and reverse primers (Alta Bioscience, University of Birmingham)
and Taqman probes (Eurogentec) listed in Table S10. Taqman
probes were synthesised containing a 59 FAM reporter dye and a
39 TAMRA quencher. All primers and probes were designed using
the Primer Express software program (Applied Biosystems).
PCR reactions were prepared in a final volume of 25 ml
containing 1x Taqman Universal PCR Mastermix (Applied
Biosystems), 300 nM forward and reverse primers, 100 nM probe
and either 0.5 ng or 5 ng input DNA. Amplification and detection
were performed using an ABI Prism 7500 Sequence Detection
System (Applied Biosystems). Thermal cycling conditions com-
prised an initial, uracil-N glycosylase incubation (2 min, 50uC),
AmpliTaq Gold activation step (10 min, 95uC) and 40 rounds of
amplification (denaturation for 15 s at 95uC, annealing and
extension for 1 min at 60uC). All test samples were run in
duplicate and template-negative reactions served as controls. Each
experiment also contained serial dilutions of a calibrator DNA
derived from the X50-7 cell line corresponding to 10, 102 103, 104
and 105 gene copies (based on 1 diploid cell being equivalent to
6.6 pg DNA), which were used to generate a standard curve for
each target gene.
Real time changes in fluorescence were analysed by the SDS
v1.7 software program (Applied Biosystems) and used to determine
the Ct value for each sample at which the fluorescence exceeded a
threshold value. For each gene, the Ct values for the serial
dilutions of the calibrator DNA were used to construct a standard
curve from which the copy number of the unknown samples could
be extrapolated. To determine if a target sequence was amplified
or deleted, each copy number value was then normalised to the
reference sequence (CYP7A1).
Array Data Deposition
The array data associated with this work have been deposited in
the GEO database (http://www.ncbi.nlm.nih.gov/geo) with
accession number GSE34573.
Supporting Information
Figure S1 Expression of EBV genes and EBV genome
status of samples used in this study. The expression of the
EBV-encoded genes BARF1, LMP1, LMP2 and EBNA1 was
determined by RT-PCR using the primers listed in Table S8.
Products were separated by agarose gel electrophoresis and
visualised under U.V. light after staining with ethidium bromide.
Cellular GAPDH expression was used as a positive control. The
primers used in the detection of LMP1 transcripts flank the 33
base pair repeat region. Thus the variation in size of product is due
to the different numbers of repeats in the LMP1 coding sequence
in the various viral genomes. EBV gene expression in samples
YH7 and YH8 was determined in separate experiments (not
shown). EBV genome status was determined by PCR as described
in the Methods. Samples HK4 and C666-1 were examined
separately (not shown).
(TIF)
Table S1 A priori defined, putative tumour-related
genes upregulated in at least 25% of samples. X = copy
number data not applicable on the X chromosome. *NA = not
available. U = upregulated in other cancers. D = downregulated
in other cancers.
(XLS)
Table S2 A priori defined, putative tumour-related
genes downregulated in at least 25% of samples. X =
copy number data not applicable on the X chromosome. *NA =
not available. U = upregulated in other cancers. D =
downregulated in other cancers.
(XLS)
Table S3 TPGs are not enriched with increasing
frequency of genomic gain.
(DOC)
Table S4 Deletion peaks identified by GISTIC analysis.
(XLS)
Table S5 Gain peaks identified by GISTIC analysis.
(XLS)
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Table S6 Genomic q-pcr validation of SNP array-
predicted copy number. The numbers represent the genome
copy number determined by SNP array analysis and by q-pcr.
(XLS)
Table S7 Proportion of TSGs within homozygous dele-
tions.
(DOC)
Table S8 Primers used for RT-PCR detection of EBV-
specific latent gene transcripts. The GAPDH gene was used
as a positive control. The LMP1-specific primers flank the 33 base
pair repeat region within the coding sequence. The pcr product
size is therefore variable due to the different numbers of repeat
units found in different virus strains.
(DOC)
Table S9 Antibodies Used for IHC.
(DOC)
Table S10 Primers and probes used for q-PCR.
(DOC)
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